165 related articles for article (PubMed ID: 30726969)
1. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Vestergaard ET; Hjelholt AJ; Kuhre RE; Møller N; Larraufie P; Gribble FM; Reimann F; Jessen N; Holst JJ; Jørgensen JOL
J Clin Endocrinol Metab; 2019 Jul; 104(7):2581-2592. PubMed ID: 30726969
[TBL] [Abstract][Full Text] [Related]
2. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
[TBL] [Abstract][Full Text] [Related]
3. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
4. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
[TBL] [Abstract][Full Text] [Related]
5. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
7. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
8. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
9. Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1.
Jepsen SL; Vestergaard ET; Larraufie P; Gribble FM; Reimann F; Jørgensen JOL; Holst JJ; Kuhre RE
J Clin Endocrinol Metab; 2020 Jan; 105(1):266-75. PubMed ID: 31608930
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Scacchi M; Orsini F; Cattaneo A; Grasso A; Filippini B; Pecori Giraldi F; Fatti LM; Moro M; Cavagnini F
Eur J Endocrinol; 2010 Aug; 163(2):201-6. PubMed ID: 20460421
[TBL] [Abstract][Full Text] [Related]
11. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
12. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Blachère JC; Pérusse F; Bukowiecki LJ
Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
[TBL] [Abstract][Full Text] [Related]
14. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.
Salgin B; Marcovecchio ML; Humphreys SM; Hill N; Chassin LJ; Lunn DJ; Hovorka R; Dunger DB
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E454-61. PubMed ID: 19106250
[TBL] [Abstract][Full Text] [Related]
15. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Hjelholt AJ; Søndergaard E; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
Metabolism; 2020 Apr; 105():154188. PubMed ID: 32084431
[TBL] [Abstract][Full Text] [Related]
17. Leptin levels in humans are acutely suppressed by isoproterenol despite acipimox-induced inhibition of lipolysis, but not by free fatty acids.
Stumvoll M; Fritsche A; Tschritter O; Lehmann R; Wahl HG; Renn W; Häring H
Metabolism; 2000 Mar; 49(3):335-9. PubMed ID: 10726911
[TBL] [Abstract][Full Text] [Related]
18. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Halbirk M; Nørrelund H; Møller N; Schmitz O; Gøtzsche L; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjær H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1220-5. PubMed ID: 20709866
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
